Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario?-Reference-Cited by-同舟云学术

Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario?

Published:2023-07 Issue:7 Volume:26 Page:1011-1021
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Fontrier Anna-Maria,Kanavos Panos

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference49 articles.

1. We need a “made in Canada” orphan drug framework;McMillan;CMAJ,2017

2. Canadian trends and projections in prescription drug purchases: 2001-2023;Tadrous;Can J Health Technol,2021

3. An Inside Look at the Early History of the CADTH Common Drug Review in Canada;MacPhail,2017

4. Pan-Canadian Pharmaceutical Alliance (pCPA): timelines analysis and policy implications;Salek;Front Pharmacol,2019

5. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: does it lead to improved patient access?;Rawson;J Popul Ther Clin Pharmacol,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada;ClinicoEconomics and Outcomes Research;2024-05

2. Canadian Cost-Effectiveness of Coronary Artery Calcium Screening Based on the Multi-Ethnic Study of Atherosclerosis;JACC: Advances;2024-04

3. Orphan drugs approved in Canada: health technology assessment, price negotiation, and government formulary listing;Expert Opinion on Orphan Drugs;2024-02-13

4. Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies;PharmacoEconomics;2023-08-18